600062 华润双鹤
交易中 03-06 13:41:41
资讯
新帖
简况
每周股票复盘：华润双鹤（600062）平衡盐冲洗液获注册证
证券之星 · 03-01
每周股票复盘：华润双鹤（600062）平衡盐冲洗液获注册证
华润双鹤（600062）披露通过GMP符合性检查公告，2月26日股价下跌0.16%
证券之星 · 02-26
华润双鹤（600062）披露通过GMP符合性检查公告，2月26日股价下跌0.16%
华润双鹤最新公告：部分药品在国家组织集采药品协议期满品种接续采购中拟中选
证券之星 · 02-10
华润双鹤最新公告：部分药品在国家组织集采药品协议期满品种接续采购中拟中选
每周股票复盘：华润双鹤（600062）拟组建营销管理中心
证券之星 · 02-08
每周股票复盘：华润双鹤（600062）拟组建营销管理中心
华润双鹤（600062）披露关于组建营销管理中心的议案，2月5日股价上涨0.38%
证券之星 · 02-05
华润双鹤（600062）披露关于组建营销管理中心的议案，2月5日股价上涨0.38%
每周股票复盘：华润双鹤（600062）获准发行30亿公司债
证券之星 · 02-01
每周股票复盘：华润双鹤（600062）获准发行30亿公司债
华润双鹤（600062）披露全资子公司复方醋酸钠林格注射液获药品注册证书，1月28日股价上涨0.32%
证券之星 · 01-28
华润双鹤（600062）披露全资子公司复方醋酸钠林格注射液获药品注册证书，1月28日股价上涨0.32%
华润双鹤最新公告：公司公开发行公司债券获得中国证监会批复
证券之星 · 01-26
华润双鹤最新公告：公司公开发行公司债券获得中国证监会批复
华润双鹤（600062）披露2026年预计发生日常关联交易公告，1月23日股价上涨0.54%
证券之星 · 01-23
华润双鹤（600062）披露2026年预计发生日常关联交易公告，1月23日股价上涨0.54%
每周股票复盘：华润双鹤（600062）DC6001片获FDA临床试验许可
证券之星 · 01-18
每周股票复盘：华润双鹤（600062）DC6001片获FDA临床试验许可
华润双鹤（600062）披露拟在珠海华润银行开展多项金融业务，1月15日股价下跌0.27%
证券之星 · 01-15
华润双鹤（600062）披露拟在珠海华润银行开展多项金融业务，1月15日股价下跌0.27%
华润双鹤最新公告：小儿复方氨基酸注射液(19AA-I-SF)获得药品补充申请批准通知书
证券之星 · 01-14
华润双鹤最新公告：小儿复方氨基酸注射液(19AA-I-SF)获得药品补充申请批准通知书
华润双鹤(600062.SH)子公司DC6001片获得FDA药物临床试验默示许可
智通财经 · 01-12
华润双鹤(600062.SH)子公司DC6001片获得FDA药物临床试验默示许可
每周股票复盘：华润双鹤（600062）参与设立10亿基金完成备案
证券之星 · 01-11
每周股票复盘：华润双鹤（600062）参与设立10亿基金完成备案
华润双鹤（600062）披露召开2026年第一次临时股东会通知，1月7日股价下跌0.38%
证券之星 · 01-07
华润双鹤（600062）披露召开2026年第一次临时股东会通知，1月7日股价下跌0.38%
华润双鹤(600062.SH)子公司北京万辉双鹤药业通过GMP符合性检查
智通财经 · 01-07
华润双鹤(600062.SH)子公司北京万辉双鹤药业通过GMP符合性检查
华润双鹤（600062）披露参与设立华润医药产业投资基金二期完成基金备案，1月5日股价上涨1.37%
证券之星 · 01-05
华润双鹤（600062）披露参与设立华润医药产业投资基金二期完成基金备案，1月5日股价上涨1.37%
每周股票复盘：华润双鹤（600062）子公司获药品注册证书
证券之星 · 01-02
每周股票复盘：华润双鹤（600062）子公司获药品注册证书
华润双鹤（600062）披露设立华润双鹤产业基金完成基金备案，12月31日股价下跌0.38%
证券之星 · 2025-12-31
华润双鹤（600062）披露设立华润双鹤产业基金完成基金备案，12月31日股价下跌0.38%
华润双鹤（600062）披露全资子公司腹膜透析液系列药品获注册证书，12月30日股价上涨0.11%
证券之星 · 2025-12-30
华润双鹤（600062）披露全资子公司腹膜透析液系列药品获注册证书，12月30日股价上涨0.11%
加载更多
公司概况
公司名称：
华润双鹤药业股份有限公司
所属行业：
医药制造业
上市日期：
1997-05-22
主营业务：
华润双鹤药业股份有限公司的主营业务是慢病业务、专科业务和输液业务三大业务。公司的主要产品是输液业务平台、慢病业务平台、专科业务平台、原料药、复方利血平氨苯蝶啶片(0号)、左炔诺孕酮片(金毓婷)、胞磷胆碱钠片(诺百益)、缬沙坦氢氯噻嗪片(复穗悦)、软袋(含直立式)。
发行价格：
6.69
{"stockData":{"symbol":"600062","market":"SH","secType":"STK","nameCN":"华润双鹤","latestPrice":18.08,"timestamp":1772775701000,"preClose":17.94,"halted":0,"volume":3655883,"delay":0,"changeRate":0.0078,"floatShares":1033000000,"shares":1039000000,"eps":1.5213,"marketStatus":"交易中","change":0.14,"latestTime":"03-06 13:41:41","open":17.94,"high":18.09,"low":17.86,"amount":65826500,"amplitude":0.0128,"askPrice":18.08,"askSize":47,"bidPrice":18.07,"bidSize":147,"shortable":0,"etf":0,"ttmEps":1.5213,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1772780400000},"marketStatusCode":2,"adr":0,"adjPreClose":17.94,"symbolType":"stock","openAndCloseTimeList":[[1772760600000,1772767800000],[1772773200000,1772780400000]],"highLimit":19.73,"lowLimit":16.15,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1038757509,"isCdr":false,"pbRate":1.65,"roa":"--","peRate":11.884572,"roe":"12.34%","epsLYR":1.5838,"committee":-0.039559,"marketValue":18781000000,"turnoverRate":0.0035,"status":0,"floatMarketCap":18676000000},"requestUrl":"/m/hq/s/600062","defaultTab":"news","newsList":[{"id":"2616784393","title":"每周股票复盘：华润双鹤（600062）平衡盐冲洗液获注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2616784393","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616784393?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:00","pubTimestamp":1772301642,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，华润双鹤报收于18.4元，较上周的18.31元上涨0.49%。本周，华润双鹤2月26日盘中最高价报18.58元。来自公司公告汇总：固体制剂、注射剂等多条生产线通过GMP符合性检查。来自公司公告汇总：平衡盐冲洗液国内市场规模达5,585万元，已有多家企业布局。华润双鹤全资子公司西安京西双鹤药业有限公司研发的平衡盐冲洗液获得国家药品监督管理局颁发的药品注册证书，规格为500ml、1000ml，注册分类为化学药品3类，视同通过一致性评价。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000561.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0010","600062","BK0028","BK0239","BK0185","BK0175"],"gpt_icon":0},{"id":"2614023937","title":"华润双鹤（600062）披露通过GMP符合性检查公告，2月26日股价下跌0.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614023937","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614023937?lang=zh_cn&edition=full","pubTime":"2026-02-26 22:49","pubTimestamp":1772117352,"startTime":"0","endTime":"0","summary":"截至2026年2月26日收盘，华润双鹤报收于18.46元，较前一交易日下跌0.16%，最新总市值为191.75亿元。该股当日开盘18.53元，最高18.58元，最低18.42元，成交额达9432.26万元，换手率为0.49%。近日，华润双鹤药业股份有限公司收到北京市药品监督管理局颁发的《药品GMP符合性检查告知书》，公司固体制剂车间硬胶囊剂生产线、注射剂车间小容量注射剂K线、冻干车间半固体制剂生产线通过GMP符合性检查。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600037498.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0185","600062","BK0010","BK0239","BK0028","BK0188"],"gpt_icon":0},{"id":"2610291648","title":"华润双鹤最新公告：部分药品在国家组织集采药品协议期满品种接续采购中拟中选","url":"https://stock-news.laohu8.com/highlight/detail?id=2610291648","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610291648?lang=zh_cn&edition=full","pubTime":"2026-02-10 17:27","pubTimestamp":1770715647,"startTime":"0","endTime":"0","summary":"华润双鹤(600062.SH)公告称，2026年2月9日，公司及部分下属子公司的缬沙坦氢氯噻嗪片、硝苯地平缓释片(Ⅱ)、硝苯地平控释片、厄贝沙坦分散片、依诺肝素钠注射液等药品拟中选集采药品协议期满品种接续采购，上述主要拟中选药品系公司参与本次接续采购的药品中收入规模排名前五的品种，除上述主要拟中选药品外，公司另有阿法骨化醇软胶囊等48个药品参与本次接续采购并拟中选。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021000028171.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0175","BK0028","BK0239","BK0010","600062","BK0188"],"gpt_icon":0},{"id":"2609526859","title":"每周股票复盘：华润双鹤（600062）拟组建营销管理中心","url":"https://stock-news.laohu8.com/highlight/detail?id=2609526859","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609526859?lang=zh_cn&edition=full","pubTime":"2026-02-08 02:34","pubTimestamp":1770489252,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，华润双鹤报收于18.68元，较上周的18.76元下跌0.43%。本周，华润双鹤2月6日盘中最高价报18.88元。华润双鹤当前最新总市值194.04亿元，在化学制药板块市值排名26/150，在两市A股市值排名1085/5186。本周关注点公司公告汇总：华润双鹤拟组建营销管理中心，以推进营销资源整合。公司公告汇总华润双鹤第十届董事会第十七次会议于2026年2月5日以通讯方式召开，11名董事全部出席。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800000813.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0175","BK0188","BK0010","BK0028","600062","BK0185"],"gpt_icon":0},{"id":"2609294309","title":"华润双鹤（600062）披露关于组建营销管理中心的议案，2月5日股价上涨0.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609294309","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609294309?lang=zh_cn&edition=full","pubTime":"2026-02-05 22:30","pubTimestamp":1770301842,"startTime":"0","endTime":"0","summary":"截至2026年2月5日收盘，华润双鹤报收于18.73元，较前一交易日上涨0.38%，最新总市值为194.56亿元。该股当日开盘18.69元，最高18.81元，最低18.65元，成交额达1.22亿元，换手率为0.63%。华润双鹤药业股份有限公司于2026年2月5日召开第十届董事会第十七次会议，会议通知于2026年2月2日以邮件方式发出，会议以通讯方式举行，11名董事全部出席。会议审议通过了《关于2026年境外佣金预算的议案》和《关于组建营销管理中心的议案》。两项议案均获全票通过。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500039774.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0239","BK0188","BK0010","BK0028","600062","BK0175"],"gpt_icon":0},{"id":"2608774020","title":"每周股票复盘：华润双鹤（600062）获准发行30亿公司债","url":"https://stock-news.laohu8.com/highlight/detail?id=2608774020","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608774020?lang=zh_cn&edition=full","pubTime":"2026-02-01 03:22","pubTimestamp":1769887333,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，华润双鹤报收于18.76元，较上周的18.72元上涨0.21%。本周，华润双鹤1月27日盘中最高价报19.08元。本周关注点公司公告汇总：华润双鹤获证监会批复，同意其向专业投资者公开发行面值总额不超过30亿元的公司债券。该批复自同意注册之日起24个月内有效，公司可在注册有效期内分期发行公司债券。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100001124.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0188","BK0185","600062","BK0175","BK0239","BK0028"],"gpt_icon":0},{"id":"2606102957","title":"华润双鹤（600062）披露全资子公司复方醋酸钠林格注射液获药品注册证书，1月28日股价上涨0.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606102957","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606102957?lang=zh_cn&edition=full","pubTime":"2026-01-28 22:53","pubTimestamp":1769611990,"startTime":"0","endTime":"0","summary":"截至2026年1月28日收盘，华润双鹤报收于18.85元，较前一交易日上涨0.32%，最新总市值为195.81亿元。该股当日开盘18.93元，最高19.03元，最低18.76元，成交额达1.78亿元，换手率为0.91%。近日，华润双鹤发布关于全资子公司西安京西双鹤药业有限公司复方醋酸钠林格注射液获得药品注册证书的公告。公告显示，西安京西双鹤药业有限公司收到国家药监局颁发的复方醋酸钠林格注射液《药品注册证书》，规格为250ml、500ml，注册分类为化学药品3类，视同通过一致性评价。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800043287.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0188","600062","BK0239","BK0010","BK0028","BK0175"],"gpt_icon":0},{"id":"2606216004","title":"华润双鹤最新公告：公司公开发行公司债券获得中国证监会批复","url":"https://stock-news.laohu8.com/highlight/detail?id=2606216004","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606216004?lang=zh_cn&edition=full","pubTime":"2026-01-26 18:19","pubTimestamp":1769422768,"startTime":"0","endTime":"0","summary":"华润双鹤(600062.SH)公告称，公司近日收到中国证监会出具的批复，同意公司向专业投资者公开发行面值总额不超过30亿元公司债券的注册申请。该批复自同意注册之日起24个月内有效，公司在注册有效期内可以分期发行公司债券。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600024827.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0010","BK0028","600062","BK0188","BK0185","BK0175"],"gpt_icon":0},{"id":"2605440687","title":"华润双鹤（600062）披露2026年预计发生日常关联交易公告，1月23日股价上涨0.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605440687","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605440687?lang=zh_cn&edition=full","pubTime":"2026-01-23 22:36","pubTimestamp":1769178980,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，华润双鹤报收于18.72元，较前一交易日上涨0.54%，最新总市值为194.46亿元。该股当日开盘18.66元，最高18.72元，最低18.62元，成交额达1.54亿元，换手率为0.8%。公司近日发布公告称，华润双鹤药业股份有限公司于2026年1月23日召开2026年第一次临时股东会，审议通过了关于2026年预计发生日常关联交易的议案。出席会议的股东所持有表决权股份数占公司总股本的62.8986%。涉及关联交易的议案已由控股股东及关联方回避表决。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300043261.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","600062","BK0239","BK0175","BK0010","BK0028","BK0188"],"gpt_icon":0},{"id":"2604230169","title":"每周股票复盘：华润双鹤（600062）DC6001片获FDA临床试验许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2604230169","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604230169?lang=zh_cn&edition=full","pubTime":"2026-01-18 03:26","pubTimestamp":1768677970,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，华润双鹤报收于18.54元，较上周的18.65元下跌0.59%。本周关注点公司公告汇总：DC6001片获FDA药物临床试验默示许可，适应症为Stargardt病。公司公告汇总华润双鹤全资子公司北京双鹤润创科技有限公司申报的DC6001片已获得FDA新药临床试验默示许可，可开展临床试验。该药品适应症为Stargardt病，此前已获国家药监局临床试验批准，并于2025年11月获FDA罕见儿科疾病药物认定。目前国内已有2家生产企业获批，华润双鹤市场份额居首。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800000942.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600062","BK0010","BK0175","BK0239","BK0028","BK0188","BK0185"],"gpt_icon":0},{"id":"2603986184","title":"华润双鹤（600062）披露拟在珠海华润银行开展多项金融业务，1月15日股价下跌0.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603986184","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603986184?lang=zh_cn&edition=full","pubTime":"2026-01-15 22:34","pubTimestamp":1768487655,"startTime":"0","endTime":"0","summary":"截至2026年1月15日收盘，华润双鹤报收于18.65元，较前一交易日下跌0.27%，最新总市值为193.73亿元。公司近日发布公告称，华润双鹤药业股份有限公司拟在珠海华润银行办理承兑汇票、存款、理财和融资业务，其中承兑汇票年度总额不超过2亿元，存款余额不超过3亿元，理财年度总额不超过2亿元，融资年度总额不超过3亿元。相关业务有效期分别为1年或2年，需经股东会审议批准。该事项已作为华润双鹤2026年第一次临时股东会会议文件提交审议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500041125.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0028","BK0188","161121","BK0010","BK0175","BK0239","600062"],"gpt_icon":0},{"id":"2603699118","title":"华润双鹤最新公告：小儿复方氨基酸注射液(19AA-I-SF)获得药品补充申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2603699118","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603699118?lang=zh_cn&edition=full","pubTime":"2026-01-14 17:25","pubTimestamp":1768382746,"startTime":"0","endTime":"0","summary":"华润双鹤公告称，公司收到国家药监局颁发的小儿复方氨基酸注射液《药品补充申请批准通知书》，同意增加500ml:50g规格。华润双鹤现有小儿复方氨基酸注射液，为满足不同患者人群的用药需求，于2021年启动增加该药品500ml:50g的补充研究工作。根据国家相关政策规定，本次获得《药品补充申请批准通知书》视同通过一致性评价。2024年国内医疗市场和零售市场小儿复方氨基酸注射液销售总额为2.75亿元人民币，其中华润双鹤市场份额为75.67%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400029185.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600062","BK0239","BK0185","BK0010","BK0175","BK0188","BK0028"],"gpt_icon":0},{"id":"2602137905","title":"华润双鹤(600062.SH)子公司DC6001片获得FDA药物临床试验默示许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2602137905","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602137905?lang=zh_cn&edition=full","pubTime":"2026-01-12 18:05","pubTimestamp":1768212316,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润双鹤(600062.SH)发布公告，公司全资子公司北京双鹤润创科技有限公司(简称“双鹤润创”)就DC6001片向FDA(即“美国食品药品监督管理局”)提交的新药临床试验申请(简称“IND”)生效，该药品已进入可推进临床试验的阶段。DC6001片处于临床研发早期阶段，有待临床试验确证安全性、疗效和质量可控性，存在客观失败率等风险。根据美国药品注册相关的法律法规要求，该药品尚需在美国开展一系列临床研究并经美国药品审评部门审批通过后，方可上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1391705.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华润双鹤(600062.SH)子公司DC6001片获得FDA药物临床试验默示许可","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0175","BK0010","BK0239","BK0185","BK0188","600062","BK0028"],"gpt_icon":0},{"id":"2602536794","title":"每周股票复盘：华润双鹤（600062）参与设立10亿基金完成备案","url":"https://stock-news.laohu8.com/highlight/detail?id=2602536794","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602536794?lang=zh_cn&edition=full","pubTime":"2026-01-11 04:23","pubTimestamp":1768076587,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，华润双鹤报收于18.65元，较上周的18.29元上涨1.97%。本周，华润双鹤1月7日盘中最高价报18.67元。本周关注点公司公告汇总：华润双鹤参与设立10亿元规模医药产业投资基金二期已完成备案。公司公告汇总：华润双鹤将于2026年1月23日召开第一次临时股东会审议多项议案。公司公告汇总华润双鹤药业股份有限公司认缴出资4,000万元参与设立华润(成都)医药产业股权投资基金合伙企业，基金目标募集规模为10亿元人民币。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100001482.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","600062","BK0239","BK0185","BK0188","BK0028","BK0175"],"gpt_icon":0},{"id":"2601015908","title":"华润双鹤（600062）披露召开2026年第一次临时股东会通知，1月7日股价下跌0.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601015908","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601015908?lang=zh_cn&edition=full","pubTime":"2026-01-07 22:32","pubTimestamp":1767796337,"startTime":"0","endTime":"0","summary":"截至2026年1月7日收盘，华润双鹤报收于18.55元，较前一交易日下跌0.38%，最新总市值为192.69亿元。近日，华润双鹤发布关于召开2026年第一次临时股东会的通知。公告显示，公司将于2026年1月23日召开2026年第一次临时股东会，会议采取现场投票与网络投票相结合的方式，股权登记日为2026年1月16日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700039072.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0175","BK0185","BK0188","BK0239","BK0028","600062"],"gpt_icon":0},{"id":"2601790108","title":"华润双鹤(600062.SH)子公司北京万辉双鹤药业通过GMP符合性检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2601790108","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601790108?lang=zh_cn&edition=full","pubTime":"2026-01-07 18:06","pubTimestamp":1767780409,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润双鹤(600062.SH)发布公告，近日，公司全资子公司北京万辉双鹤药业有限责任公司收到北京市药品监督管理局颁发的《药品GMP符合性检查告知书》(编号：京药监药GMP[2025]020140)。本次检查是阿法骨化醇软胶囊上市前的首次药品GMP符合性检查。该检查项目是在原有厂房、设备情况下的检查，未投入资金。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389923.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","600062","BK0185","BK0175","BK0188","BK0010","BK0239"],"gpt_icon":0},{"id":"2601887505","title":"华润双鹤（600062）披露参与设立华润医药产业投资基金二期完成基金备案，1月5日股价上涨1.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601887505","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601887505?lang=zh_cn&edition=full","pubTime":"2026-01-05 22:28","pubTimestamp":1767623303,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，华润双鹤报收于18.54元，较前一交易日上涨1.37%，最新总市值为192.59亿元。公司近日发布公告称，华润双鹤药业股份有限公司认缴出资4,000万元参与设立华润(成都)医药产业股权投资基金合伙企业，基金目标募集规模为10亿元人民币。该基金已于2025年12月30日在中国证券投资基金业协会完成备案，备案编码为SBLL28，基金管理人为深圳市华润资本股权投资有限公司，托管人为招商银行股份有限公司。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500040179.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0175","BK0188","BK1570","BK1191","BK0010","03320","BK0028","600062","BK0185"],"gpt_icon":0},{"id":"2600039433","title":"每周股票复盘：华润双鹤（600062）子公司获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2600039433","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600039433?lang=zh_cn&edition=full","pubTime":"2026-01-02 04:22","pubTimestamp":1767298932,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，华润双鹤报收于18.49元，较上周的18.57元下跌0.43%。本周，华润双鹤12月22日盘中最高价报18.6元。上海长富于2023年2月启动研发，2024年8月提交上市申请并获受理，2025年12月获批。截至目前累计研发投入2,044.57万元。华润双鹤收到国家药监局签发的羟钴胺注射液《药物临床试验批准通知书》，同意开展用于儿童甲基丙二酸血症伴或不伴同型半胱氨酸血症患者代谢紊乱的临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200001297.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0185","600062","BK0188","BK0010","BK0175"],"gpt_icon":0},{"id":"2595778265","title":"华润双鹤（600062）披露设立华润双鹤产业基金完成基金备案，12月31日股价下跌0.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595778265","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595778265?lang=zh_cn&edition=full","pubTime":"2025-12-31 18:13","pubTimestamp":1767176016,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，华润双鹤报收于18.29元，较前一交易日下跌0.38%，最新总市值为189.99亿元。公司近日发布公告称，华润双鹤药业股份有限公司认缴出资8,300万元参与设立华润双鹤生物医药产业基金投资合伙企业，基金目标募集规模为5亿元。该基金已完成在中国证券投资基金业协会的备案，备案编码为SBML96，管理人为深圳市华润资本股权投资有限公司，托管人为中国工商银行股份有限公司，备案日期为2025年12月29日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100034027.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0175","BK0185","BK0188","BK0239","BK0028","600062"],"gpt_icon":0},{"id":"2595793001","title":"华润双鹤（600062）披露全资子公司腹膜透析液系列药品获注册证书，12月30日股价上涨0.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595793001","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595793001?lang=zh_cn&edition=full","pubTime":"2025-12-30 17:44","pubTimestamp":1767087894,"startTime":"0","endTime":"0","summary":"截至2025年12月30日收盘，华润双鹤报收于18.36元，较前一交易日上涨0.11%，最新总市值为190.72亿元。该股当日开盘18.31元，最高18.39元，最低18.24元，成交额达6561.9万元，换手率为0.35%。公司近日发布公告称，其全资子公司上海长征富民金山制药有限公司获得国家药监局颁发的低钙腹膜透析液和腹膜透析液系列药品的《药品注册证书》，规格均为2000ml，注册分类为化学药品3类，视同通过一致性评价。截至目前累计研发投入2,044.57万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000030256.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0175","BK0188","BK0010","BK0028","600062","BK0185"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772775714456,"stockEarnings":[{"period":"1week","weight":-0.0282},{"period":"1month","weight":-0.0344},{"period":"3month","weight":-0.0452},{"period":"6month","weight":-0.0695},{"period":"1year","weight":-0.0299},{"period":"ytd","weight":-0.0191}],"compareEarnings":[{"period":"1week","weight":-0.0092},{"period":"1month","weight":0.01},{"period":"3month","weight":0.0527},{"period":"6month","weight":0.0777},{"period":"1year","weight":0.2294},{"period":"ytd","weight":0.0352}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华润双鹤药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"57726人(较上一季度增加0.51%)","perCapita":"17894股","listingDate":"1997-05-22","address":"北京市朝阳区望京利泽东二路1号","registeredCapital":"103875万元","survey":" 华润双鹤药业股份有限公司的主营业务是慢病业务、专科业务和输液业务三大业务。公司的主要产品是输液业务平台、慢病业务平台、专科业务平台、原料药、复方利血平氨苯蝶啶片(0号)、左炔诺孕酮片(金毓婷)、胞磷胆碱钠片(诺百益)、缬沙坦氢氯噻嗪片(复穗悦)、软袋(含直立式)。","listedPrice":6.69},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华润双鹤(600062)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华润双鹤(600062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华润双鹤,600062,华润双鹤股票,华润双鹤股票老虎,华润双鹤股票老虎国际,华润双鹤行情,华润双鹤股票行情,华润双鹤股价,华润双鹤股市,华润双鹤股票价格,华润双鹤股票交易,华润双鹤股票购买,华润双鹤股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华润双鹤(600062)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华润双鹤(600062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}